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Background-—Angina is common both before and after myocardial infarction (MI). Whether the change in angina status within the
first 30 days after MI is associated with subsequent readmission and angina persistence is unknown.
Methods and Results-—We studied 2915 MI patients enrolled at 24 hospitals in the Translational Research Investigating
Underlying Disparities in Acute Myocardial Infarction Patients’ Health Status (TRIUMPH) registry. Angina before and 30 days after
MI was assessed with the Seattle Angina Questionnaire. Patients were divided into angina-free pre- and post-MI (/), resolved
angina (+/), new angina (/+), and persistent angina (+/+) groups. Multivariable proportional hazards and hierarchical modified
Poisson models were performed to assess the association of each group with all-cause readmission, readmission for MI or
unplanned revascularization, and angina persistence at 1 year. Overall, 1293 patients (44%) had angina before their MI and 849
(29%) reported angina within 30 days of discharge. Patients with post-MI angina were more likely to be younger, nonwhite, and
uninsured. Compared with patients who were angina-free pre- and post-MI, 1-year all-cause readmission risks were significantly
higher for patients with persistent angina (hazard ratio [HR], 1.35; 95% CI 1.06–1.71) or new angina (HR, 1.40; 95% CI, 1.08–1.82).
At 1 year, angina was present in 22% of patients and was more likely if angina was persistent (HR, 3.55; 95% CI, 3.05–4.13) or new
(HR, 3.38; 95% CI, 2.59–4.42) at 30 days compared with patients who were angina-free pre- and post-MI.
Conclusions-—Post-MI angina, whether new or persistent, is associated with higher likelihood of readmission. Prioritizing post-MI
angina management is a potential means of improving 1-year outcomes. ( J Am Heart Assoc. 2016;5:e003205 doi: 10.1161/
JAHA.116.003205)
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A ngina is common after acute myocardial infarction (MI)and has substantial impact on patient-reported quality of
life, treatment satisfaction, and costs of care.1–4 Approximately
25% of patients report angina symptoms in the year after MI.5,6
Having angina before an MI is highly predictive of angina after
MI. However, many patients have resolution of angina and
some develop new angina that was not present before their
MI.7 The importance of change in angina status is unknown,
especially with regard to its association with long-term angina
symptoms (eg, 1 year post-MI) and readmission.
Avoidance of unnecessary readmission after MI is a focus
of the Affordable Care Act, and readmission rates are publicly
reported.8 Though current efforts to prevent readmissions
have targeted the initial 30 days after MI, high rates of
readmission are observed in the first year post-MI and also
warrant efforts to avoid them, particularly as health care
moves to accountable care organizations.9 Thus, the initial
clinical assessment after discharge could identify patients at
high risk for hospitalization and continued angina symptoms.
Previous studies have reported demographic and clinical
variables associated with readmission,10,11 but the impact of
pre- and post-MI angina has not been assessed.
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ORIGINAL RESEARCH
To address this gap in knowledge, we used the Transla-
tional Research Investigating Underlying Disparities in Acute
Myocardial Infarction Patients’ Health Status (TRIUMPH)
prospective registry to examine patients with angina before
and/or after MI. Our objectives were to: (1) report patterns of
change in angina symptom status immediately before and
after MI; (2) describe baseline characteristics of patients
according to change in angina symptoms; and (3) examine the
association between change in angina symptoms and risk of
readmission and angina status at 1 year.
Methods
Study Population
Details of the TRIUMPH registry have been previously
described.12 In brief, TRIUMPH is a prospective multicenter
registry of patients with ST-elevation (STEMI) or non-ST-
elevation MI (NSTEMI). Eligible patients were ≥18 years old
with objective criteria for MI (biomarker evidence of myocar-
dial injury and clinical features of ischemia) treated at one of
24 US hospitals within 24 hours of original presentation.
From April 2005 to December 2008, 4340 patients were
enrolled. All participants provided written, informed consent.
Institutional review board approval was obtained at each
participating institution.
In order to study the change in angina symptoms from
baseline to 30 days after MI, we excluded all patients without
complete angina data at these time points. Of the 4340
patients in the full cohort, 24 died during the index hospital-
ization (0.6%), 16 lacked baseline angina data (0.4%), and 1385
lacked angina data at 30 days (31.9%). Compared with our
study population, subjects missing angina data at 30 days
were more likely to be younger, black, and uninsured, with
modestly higher rates of angina at baseline (Table S1), and the
observed data were weighted to account for patients with
missing data, as described in the Statistical Analysis section
below. Our final analytic sample included 2915 patients.
Data Collection
Trained research personnel performed detailed baseline
interviews within 24 to 72 hours of initial presentation. These
interviews included general sociodemographic information,
past medical history, and assessments of angina symptoms
using the 19-item Seattle Angina Questionnaire (SAQ).13
Patients’ general mental and physical function was assessed
with the 12-item short form (SF-12),14 and depressive
symptoms were measured with the 9-item Patient Health
Questionnaire (PHQ-9).15 The SAQ has a 4-week recall period,
such that the baseline assessment quantified patients’ angina
burden over the 4 weeks before their MI. Additional informa-
tion was obtained by retrospective abstraction of the
in-hospital medical record and included presenting clinical
features, in-hospital treatment, in-hospital events, discharge
medications, discharge recommendations, and final diag-
noses. Follow-up assessments were conducted at 1 month,
6 months, and 1 year, either by phone or during an in-home
visit. Patients responded to the full SAQ at each time
point and reported interval hospitalizations, procedures,
medication use, smoking status, and cardiac rehabilitation
attendance.
The primary exposure variable was the presence of angina
before and 30 days after patients’ MIs. To quantify angina, we
used the SAQ Angina Frequency score, which has been shown
to be a highly valid assessment of angina as compared with
daily diaries.16 For these analyses, angina was dichotomized
as any (SAQ Angina Frequency score <100) or no angina (SAQ
Angina Frequency score=100).
Outcomes
The primary outcome of this study was the incidence of all-
cause readmission within 1 year after MI. Secondary outcomes
include (1) readmission for MI or unplanned (nonelective)
revascularization at 1 year and (2) angina symptoms at 1 year.
Hospitalizations and procedures reported by patients during
follow-up triggered collection of medical records, which were
Figure 1. Angina status before and after myocardial infarction. Patients were assessed
for angina symptoms before and after admission for myocardial infarction and classified in
4 groups describing the change in angina symptoms.
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Age, y 60.912.0 60.111.7 57.511.8 56.712.4 <0.001
Male 860 (67.3) 562 (71.3) 291 (57.6) 225 (65.4) <0.001
White race 966 (75.7) 586 (74.5) 317 (63.1) 229 (66.8) <0.001
BMI 29.66.4 29.76.0 29.66.3 29.76.6 0.861
High school education or greater 1051 (82.5) 644 (82.4) 391 (77.5) 278 (81.1) 0.008
Uninsured/self-pay 184 (14.7) 115 (14.8) 114 (23.2) 75 (22.3) <0.001
Insurance coverage for medications 979 (78.3) 590 (76.2) 347 (69.8) 231 (68.1) <0.001
Clinical history (%)
Past MI 223 (17.5) 172 (21.8) 132 (26.1) 58 (16.9) <0.001
Past PCI 210 (16.4) 168 (21.3) 130 (25.7) 58 (16.9) <0.001
Past CABG 125 (9.8) 96 (12.2) 88 (17.4) 27 (7.8) <0.001
Diabetes mellitus 345 (27.0) 229 (29.1) 183 (36.2) 83 (24.1) 0.003
Heart failure 79 (6.2) 43 (5.5) 63 (12.5) 21 (6.1) <0.001
Past stroke 54 (4.2) 35 (4.4) 35 (6.9) 11 (3.2) 0.064
Chronic lung disease 66 (5.2) 61 (7.7) 57 (11.3) 28 (8.1) <0.001
Hypertension 808 (63.2) 550 (69.8) 347 (68.7) 212 (61.6) 0.094
Dyslipidemia 602 (47.1) 450 (57.1) 253 (50.1) 156 (45.3) 0.468
Current cigarette smoking 451 (35.6) 263 (33.9) 210 (41.8) 160 (46.9) <0.001
In-hospital characteristics (%)
STEMI 615 (48.1) 347 (44.0) 186 (36.8) 170 (49.4) <0.001
Ejection fraction 49.212.5 48.612.9 50.512.7 48.813.1 0.084
Multivessel disease 585 (48.5) 375 (50.3) 219 (48.6) 166 (50.6) 0.804
Angina frequency at baseline (%) <0.001
Daily 0 (0.0) 33 (4.2) 46 (9.1) 0 (0.0)
Weekly 0 (0.0) 208 (26.4) 180 (35.6) 0 (0.0)
Monthly 0 (0.0) 547 (69.4) 279 (55.2) 0 (0.0)
None 1278 (100.0) 0 (0.0) 0 (0.0) 344 (100.0)
SF-12 Mental component score 52.010.4 49.911.1 45.012.4 51.310.2 <0.001
SF-12 Physical component score 46.710.9 40.111.9 36.312.2 44.411.7 <0.001
PHQ-9 Depression score 3.94.6 5.55.5 8.16.1 4.74.6 <0.001
Treatment characteristics
Fibrinolytic therapy 93 (7.3) 41 (5.2) 26 (5.1) 23 (6.7) 0.120
In-hospital PCI 891 (69.7) 547 (69.4) 301 (59.6) 238 (69.2) <0.001
In-hospital CABG 118 (9.2) 100 (12.7) 39 (7.7) 29 (8.4) 0.304
Residual stenosis ≥70% in at least 1 vessel 613 (48.0) 399 (50.6) 236 (46.7) 186 (54.1) 0.801
Defect-free care* 714 (55.9) 428 (54.3) 200 (58.1) 262 (51.9) 0.289
Medication/cardiac rehabilitation at 1 month (%)
Aspirin 963 (87.3) 593 (86.3) 384 (83.8) 259 (83.8) 0.038
Beta-blocker 951 (86.2) 613 (89.2) 405 (88.4) 280 (90.6) 0.087
Statin 933 (84.6) 574 (83.6) 372 (81.2) 266 (86.1) 0.226
Continued
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reviewed independently by 2 cardiologists to classify the
primary reason for hospitalization. Disagreement between the
2 cardiologists was adjudicated by a third cardiologist and, if
there was continued disagreement, up to 5 cardiologists
until consensus was achieved. Admission for unplanned
revascularization was defined as an admission for nonelec-
tive percutaneous coronary intervention (PCI) or coronary
artery bypass graft (CABG) surgery, given that PCI or CABG
performed electively within 1 month of the index MI
hospitalization was considered planned (staged) procedures
and was excluded. Patient-reported hospitalizations were
excluded from the assessment of readmission for MI or
unplanned revascularization if medical records could not be
obtained for adjudication. Angina symptoms were assessed
with the SAQ as previously described and the same
dichotomization of the SAQ Angina Frequency score was
used to define the presence of angina at 1 year. Mortality
was assessed by query of the Death Master File using
patients’ Social Security number. Outcomes were assessed
starting at the 30-day follow-up interview.
Statistical Analysis
Based on patient-reported angina status during the 4 weeks
before and after the patient’s MI, patients were divided into 4
groups: angina-free pre- and post-MI (/); resolved angina
(+/); persistent angina (+/+); and new angina (/+) post-
MI. Baseline differences in categorical variables were
assessed with chi-square or Fisher’s exact test, as appropri-
ate, and continuous variables were compared with 1-way
ANOVA.
To assess the association between angina groups and
readmission, we first performed a Kaplan–Meier analysis with
log-rank test. Next, multivariable proportional hazards models
stratified by hospitals were used for all-cause readmission and
readmission for MI or unplanned revascularization. A hierar-
chical multivariable modified Poisson model with hospital as a
random effect was used for associating the groups with the
presence of angina 1 year after MI. Angina-free patients were
used as the reference group in all analyses. Variables included
in the model were selected a priori, based upon clinical
judgment and literature review. All of the following variables
were used for each of the outcomes models (all-cause
readmission, readmission for MI or unplanned revasculariza-
tion, and angina). We included factors potentially related to
angina or hospitalization, including patient demographics
(age, race, and sex), socioeconomic factors (education,
insurance status), medical history (past heart failure, diabetes
mellitus, past lung disease, and current or recent smoking),
history of coronary heart disease (past MI, past PCI, past
CABG), patient-reported health status (SF mental and physical
scores, PHQ-9 depression score), presenting characteristics
(STEMI presentation), and inpatient care (in-hospital PCI,
residual coronary stenosis [≥70% in at least 1 vessel] and
defect-free discharge care [defined as discharge on all of the
following meds in the absence of contraindication: aspirin,
beta-blocker, angiotensin-converting enzyme/angiotensin
receptor blocker {ACE/ARB}, statin, and thienopyridine]).
We then grouped patients by the frequency of their post-MI
angina (none, daily, weekly, and monthly) and assessed the
association of angina frequency with readmission and 1-year
angina using the methods described above.
The 3 data variables with highest missing rates were PHQ
score (6.0%), SF physical component summary (4.5%), and
SF mental component summary (4.5%). Missing data were
imputed from multiple imputation models using IVEware
(University of Michigan, Ann Arbor, MI). Inverse probability
weighting was used for all multivariable models to correct
for selection bias related to patients excluded because of
lack of 30-day angina status. We used SAS (version 9.3; SAS
Institute Inc., Cary, NC), and R software (version 2.15.3; R
Foundation for Statistical Computing, Vienna, Austria) to
conduct our analyses. All analyses were prespecified, and a
2-sided P value less than 0.05 was considered statistically
significant.
Results
Of 2915 patients presenting with acute MI, 1293 (44.4%)











ACE-I/ARB 784 (71.1) 480 (69.9) 322 (70.3) 217 (70.2) 0.728
Nitrate/ranolazine 52 (4.7) 50 (7.3) 108 (23.6) 34 (11.0) <0.001
Cardiac rehabilitation participation 377 (30.5) 231 (30.5) 127 (25.8) 111 (33.2) 0.176
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; MI, myocardial infarction; PCI,
percutaneous coronary intervention; PHQ-9, the 9-item Patient Health Questionnaire; SF-12, 12-item short form; STEMI, ST-segment elevation myocardial infarction.
*Defined as discharge on all of the following meds in the absence of contraindication: aspirin, beta-blocker, ACE/ARB, statin, thienopyridine.
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post-MI, 849 patients (29.1%) reported angina. Overall, 1278
patients (43.8%) were angina-free at both time points, 788
(27.1%) had angina before admission that resolved by
30 days, 344 (11.8%) had new angina develop after their
MI, and 505 patients (17.3%) had persistent angina at 30 days
(Figure 1).
Baseline demographics and clinical characteristics differed
between the four groups (Table 1). Patients with post-MI
angina (persistent or new angina groups) were more likely to
be younger, nonwhite, and uninsured. Patients with persistent
angina, compared with patients whose angina resolved, had
more-frequent angina at baseline and were more likely to
present with NSTEMI. Patients with persistent angina also had
worse baseline physical and mental function and higher rates
of depressive symptoms. Treatment characteristics were
similar among the 4 groups, with the exception of less in-
hospital PCI use in the persistent angina group. Rates of
residual obstructive coronary disease (≥70% in at least 1
vessel) were similar across all groups. The use of evidence-
based, secondary prevention medications at the time of the
30-day follow-up visit was similar among groups, with the
exception of significantly higher use of long-acting nitrates
and ranolazine among patients with persistent angina. Less
than one third of patients attended cardiac rehabilitation in all
groups.
Kaplan–Meier curves showing time to first all-cause
readmission are shown in Figure 2A. At 1 year, there was
no significant difference in readmission rates between
patients with resolved angina and those who were angina-
free before and after their MI. However, those with angina
30 days after their MI, whether persistent or newly devel-
oped, had higher rates of readmission. Risk of readmission
for MI or unplanned (nonelective) revascularization was also
greater among patients with persistent or new angina
(Figure 2B). After multivariable adjustment, risk of all-cause
readmission was significantly higher among patients with
persistent angina (hazard ratio [HR], 1.35; 95% CI, 1.06–
1.71) and new angina (HR, 1.40; 95% CI, 1.08–1.82), as
compared with angina-free patients. Only patients with new
angina had higher rates of readmission for MI or unplanned
revascularization as compared with patients who were
angina-free (relative risk [RR], 2.18; 95% CI, 1.28–3.72;
Table 2).
We subsequently assessed whether the frequency of post-
MI angina (new or persistent) was associated with readmis-
sion rates and 1-year angina. Compared with patients without
post-MI angina, increased frequency of post-MI angina was
associated with readmission in a step-wise fashion after
adjustment (Table 3), with greater angina burden associated
with higher readmission rates.
Among 1-year survivors, the overall prevalence of angina
was 22.0%. Angina at 1 year was most frequent in the
patients who had persistent angina at 30 days (49.6%),
followed by those with new angina (38.6%) and resolved
angina (18.2%). After adjusting for covariate imbalance
between the groups, all of these groups had significantly
higher rates of angina 1 year after their MI as compared with
patients who were angina-free both before and after their MI
(9.9%) (Table 2). In addition, all frequencies of post-MI angina
(daily, weekly, or monthly) were associated with increased
likelihood of angina at 1 year (Table 3).
Figure 2. Kaplan–Meier event rates according to change in
angina status: (A) all-cause readmission and (B) readmisssion for
MI or unplanned revascularization. Events were more frequent for
patients with with new or persistent angina at 30 days post-MI.
Log-rank test demonstrated statistically significant differences
between groups. MI indicates myocardial infarction.
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An important treatment goal for patients with acute MI is the
prevention of downstream angina symptoms, which not only
adversely affect patients’ quality of life, but may also lead to
greater health care resource use. In this multicenter registry,
angina was common both before and after MI, and patients
with angina 30 days after their MI, whether persistent or
newly developed, were significantly more likely to be hospi-
talized when compared with those who remained angina-free.
Angina at 1 year after MI was common and was significantly
more likely among those patients reporting angina 30 days
after their MI.
In an era of accountable care and other efforts designed to
more efficiently use limited health care resources, intense
focus has been placed on avoiding readmissions. Thirty-day
readmission rate after MI is a publicly reported hospital quality
measure and a focus of the Hospital Readmissions Reduction
Program of the Affordable Care Act, with strong incentives or
penalties provided to optimize care.8 Readmissions within
30 days are most commonly caused by acute indications, such
as heart failure exacerbation, recurrent MI, and electrolyte
disorders,17 but this study highlights the important association
of angina symptoms with admissions after 30 days. Patients
with angina at 30 days are a high-risk group who may benefit
from targeted clinical interventions during routine clinical
follow-up to avoid late readmissions. To our knowledge, this is
the first study to describe the association of post-MI change in
angina status and readmission. Our results are consistent with
past studies demonstrating angina is common after MI7 and
associated with lower quality of life5 and increased down-
stream resource utilization.4
Differences in readmission risk are unlikely to be explained
by anatomic factors, given that we found no differences in the
rates of residual coronary stenosis at the time of index
hospitalization. Our results remained significant after adjust-
ment for functional status and depression, factors that have
been previously associated with risk for readmission. Addi-
tionally, antiangina medication use, though infrequent for all
groups, was highest among those with the highest readmis-
sion rates. Differences in hospitalization rates may have been
further exaggerated if treatment patterns were similar for all
groups, and future efforts to explore the benefits of more-
intense antianginal treatment after MI are warranted.
Clinicians should prioritize efforts to reduce angina using
medications or cardiac rehabilitation. We identify ample
opportunity for improvement, given that use of these thera-
pies was low for all patients in our study. The potential impact
of improved angina control is highlighted by the step-wise
association of angina frequency with readmission rate.
The rate of readmission for MI and unplanned revascular-
ization was also significantly higher after multivariable
adjustment among patients with newly developed angina. Of
note, our study did not distinguish between stable and
unstable angina symptoms after MI. For some patients, post-
Table 2. Risk of Readmission and Angina at 1 Year According to Change in Angina Status
Change in Angina
All-Cause Readmission at 1 Year
Readmission for MI or Unplanned













Angina-free (/) 23.3% Reference 4.0% Reference 9.9% Reference
Resolved angina (+/) 24.8% 0.91 (0.72–1.14) 5.7% 0.89 (0.52–1.53) 18.2% 1.61 (1.32–1.97)
Persistent angina (+/+) 37.1% 1.35 (1.06–1.71) 10.3% 1.67 (0.98–2.86) 49.6% 3.55 (3.05–4.13)
New angina (/+) 35.9% 1.40 (1.08–1.82) 12.9% 2.18 (1.28–3.72)* 38.6% 3.38 (2.59–4.42)
HR indicates hazard ratio; MI, myocardial infarction; RR, risk ratio.
Table 3. Risk of Readmission and Angina at 1 Year According to Frequency of Post-MI Angina




Readmission for MI or Unplanned
Revascularization at 1 Year Angina at 1 Year
Adjusted HR (95% CI) Adjusted HR (95% CI) Adjusted RR (95% CI)
No angina (n=2066, 70.9%) Reference Reference Reference
Monthly (n=568, 19.5%) 1.30 (1.06–1.60) 1.65 (1.04–2.60) 2.15 (1.66–2.78)
Weekly (n=234, 8.0%) 1.63 (1.25–2.12) 2.54 (1.48–4.33) 2.74 (2.23–3.35)
Daily (n=47, 1.6%) 2.15 (1.35–3.42) 3.56 (1.40–9.05) 1.83 (1.29–2.58)
HR indicates hazard ratio; MI, myocardial infarction; RR, risk ratio.
DOI: 10.1161/JAHA.116.003205 Journal of the American Heart Association 6















MI angina may represent unstable or progressive coronary
disease, leading to recurrent MI or need for revascularization
to improve quality of life. For others, angina at 30 days may
represent chronic stable angina that persists for many
patients to at least 1 year. Clinical follow-up should target
secondary prevention of ischemic events in addition to angina
reduction.
This study has several potential limitations. Incomplete
angina data at 30 days limited our population to two thirds of
the total TRIUMPH population. This loss to follow-up could
lead to incorrect assessment of the relationship between
change in angina and clinical endpoints. Excluded patients
were more likely to be younger, nonwhite, and uninsured, all
demographic factors that were associated with angina in this
study. Therefore, overall rates of angina may have been higher
if these patients were included. Inverse probability weighting
of all multivariable models to correct for this potential bias did
not alter the results. Severity of residual coronary disease was
determined by chart review of the coronary angiogram and
not an angiographic core laboratory. As such, we cannot
definitively exclude the possibility that higher anatomic
burden of disease led to both increased angina and rehos-
pitalization rates. Use of the SAQ for assessment of pre-MI
angina has not been previously validated and may be subject
to some recall bias, though this instrument has performed
well compared to angina diaries and other measures of health
status in multiple other patient populations. Finally, this is an
observational study and our findings may be subject to
residual confounding, despite extensive adjustment for clin-
ical and psychosocial variables.
Conclusions
Patients with early post-MI angina are at increased risk for
readmission in the first year post-MI, and angina symptoms
remain prevalent 1 year post-MI. These results highlight the
need for increased attention to routine post-MI angina
surveillance and symptom management. Future research to
examine novel strategies to reduce post-MI angina should be
undertaken in an effort to reduce readmission rates and
improve long-term angina control in this high-risk population.
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Table S1. Baseline and treatment characteristics of patients excluded due to absence of angina data at 
30 days vs. included with complete angina data 
 
Variable 







Age 57.7 ± 12.9 59.6 ± 12.0 <0.001 
Male 936 (67.6%) 1938 (66.5%) 0.475 
White race 792 (57.4% ) 2098 (72.2%) <0.001 
BMI 29.4 ± 6.5 29.7 ± 6.3 0.251 
High school education or greater 1026 (74.6%) 2364 (81.5%) <0.001 
Uninsured/self pay 376 (27.5% ) 574 (20.1% ) <0.001 
Insurance coverage for medications 911 (67.1%) 2147 (75.0%) <0.001 
Prior MI 314 (22.7%) 585 (20.1%) 0.050 
Prior PCI 275 (19.9%) 566 (19.4%) 0.735 
Prior CABG 148 (  10.7% ) 336 (  11.5% )   0.415 
Diabetes 486 (  35.1% ) 840 (  28.8% ) < 0.001 
Heart failure 159 (  11.5% ) 206 (   7.1% ) < 0.001 
Prior stroke 77 (   5.6% ) 135 (   4.6% )   0.189 
Chronic lung disease 100 (   7.2% ) 212 (   7.3% )   0.951 
Hypertension 944 (  68.2% ) 1917 (  65.8% )   0.120 
Dyslipidemia 643 (  46.4% ) 1461 (  50.1% )   0.024 
Current cigarette smoking (1 month) 564 (41.5%) 1084 (37.6%) 0.015 
STEMI 536 (38.7%) 1318 (45.2%) <0.001 
Ejection Fraction 47.5 ± 13.8 49.2 ± 12.7 <0.001 
Multi-vessel disease 609 (49.1%) 1345 (49.2%) <0.001 
Angina Frequency at baseline   0.031 
-Daily 64 (4.6%) 79 (2.7%)  
-Weekly 186 (13.4%) 388 (13.3%)  
3 
 
-Monthly 391 (28.2%) 826 (28.3%)  
-None 744 (53.7%) 1622 (55.6%)  
SF 12 Mental component score 48.9 ± 12.1 50.1 ± 11.2 0.001 
SF 12 Physical component score 41.0 ± 12.8 42.9 ± 12.2 <0.001 
PHQ-9 Depression score 5.3 ± 5.4 5.1 ± 5.3 0.386 
Fibrinolytic therapy 62 (4.5%) 183 (6.3%) 0.017 
In-hospital PCI 827 (59.7%) 1977 (67.8%) <0.001 
In-hospital CABG 111 (8.0%) 286 (9.8%) 0.057 
Residual stenosis ≥50% in at least 1 vessel 794 (57.3%) 1799 (61.7%) 0.006 
Abbreviations: BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, 
coronary artery bypass graft; STEMI, ST-segment elevation myocardial infarction 
 
 
 
